Exact Mass: 323.14

Exact Mass Matches: 323.14

Found 119 metabolites which its exact mass value is equals to given mass value 323.14, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Acremoauxin A

Acremoauxin A; 2-(3-Indolyl)propanoylmannitol

C16H21NO6 (323.1369)


An indolyl carboxylate ester obtained by formal condensation of one of the primary hydroxy groups of D-arabinitol with the carboxy group of (2R)-2-(indol-3-yl)propanoic acid.

   

Rucaparib

Rucaparib

C19H18FN3O (323.1434)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XK - Poly (adp-ribose) polymerase (parp) inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C62554 - Poly (ADP-Ribose) Polymerase Inhibitor D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor

   

Naftifine hydrochloride

Naftifine hydrochloride

C21H22ClN (323.1441)


D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent

   

Histidyltryptophyldiketopiperazine

Histidyltryptophyldiketopiperazine

C17H17N5O2 (323.1382)


   

Cyproheptadine hydrochloride

Cyproheptadine hydrochloride

C21H22ClN (323.1441)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D003879 - Dermatologic Agents > D000982 - Antipruritics D005765 - Gastrointestinal Agents D018926 - Anti-Allergic Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders[1][2].

   

Gliclazide

1-(4-methylbenzenesulfonyl)-3-{octahydrocyclopenta[c]pyrrol-2-yl}urea

C15H21N3O3S (323.1304)


Gliclazide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Gliclazide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Gliclazide is extensively metabolized by the liver; its metabolites are excreted in both urine (60-70\\%) and feces (10-20\\%). A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas D007004 - Hypoglycemic Agents

   

Cyamemazine

10-[3-(dimethylamino)-2-methylpropyl]-10H-phenothiazine-2-carbonitrile

C19H21N3S (323.1456)


N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AA - Phenothiazines with aliphatic side-chain C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Cyamemazine is a neuroleptic agent that contains the phenothiazine chromophore. Cyamemazine is often used as an anxiolytic. Cyamemazine is a potent 5-HT3 (Ki of 12 nM), 5-HT2A (Ki = 1.5 nM) and 5-HT2C (Ki of 75 nM) receptors antagonist with antipsychotic activity[1][2].

   

Dehydromonocrotaline

4,5-Dihydroxy-3,4,5-trimethyl-4,5,8,12,13,13a-hexahydro-2H-[1,6]dioxacycloundecino[2,3,4-gh]pyrrolizine-2,6(3H)-dione

C16H21NO6 (323.1369)


   

Renzapride

4-Amino-N-{1-azabicyclo[3.3.1]nonan-4-yl}-5-chloro-2-methoxybenzene-1-carboximidate

C16H22ClN3O2 (323.14)


   

Rubraca

6-fluoro-2-{4-[(methylamino)methyl]phenyl}-3,10-diazatricyclo[6.4.1.0^{4,13}]trideca-1,4,6,8(13)-tetraen-9-one

C19H18FN3O (323.1434)


L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01X - Other antineoplastic agents > L01XK - Poly (adp-ribose) polymerase (parp) inhibitors C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C62554 - Poly (ADP-Ribose) Polymerase Inhibitor D000970 - Antineoplastic Agents > D000067856 - Poly(ADP-ribose) Polymerase Inhibitors D004791 - Enzyme Inhibitors C471 - Enzyme Inhibitor

   

Cyamemazine

Cyamemazine

C19H21N3S (323.1456)


N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AA - Phenothiazines with aliphatic side-chain C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist Cyamemazine is a neuroleptic agent that contains the phenothiazine chromophore. Cyamemazine is often used as an anxiolytic. Cyamemazine is a potent 5-HT3 (Ki of 12 nM), 5-HT2A (Ki = 1.5 nM) and 5-HT2C (Ki of 75 nM) receptors antagonist with antipsychotic activity[1][2].

   
   

TEB_M324a

TEB_M324a

C16H22ClN3O2 (323.14)


CONFIDENCE Transformation product, tentative ID (Level 2b); INTERNAL_ID 2501

   

TEB_M324b *

TEB_M324b *

C16H22ClN3O2 (323.14)


CONFIDENCE Transformation product, tentative ID (Level 3 structure); INTERNAL_ID 2504

   

TEB_M324c

TEB_M324c

C16H22ClN3O2 (323.14)


CONFIDENCE Transformation product, tentative ID (Level 3 structure); INTERNAL_ID 2505

   

acetyl dicrotaline

acetyl dicrotaline

C16H21NO6 (323.1369)


   

2-(3-methoxycarbonyl-propyl) gardenamide A|genipamide

2-(3-methoxycarbonyl-propyl) gardenamide A|genipamide

C16H21NO6 (323.1369)


   

3-(4-methoxy-3-methyl-2-oxo-2H-pyran-6-yl)butyl pyroglutamate

3-(4-methoxy-3-methyl-2-oxo-2H-pyran-6-yl)butyl pyroglutamate

C16H21NO6 (323.1369)


   

(-)-monophyllidin

(-)-monophyllidin

C16H21NO6 (323.1369)


   

8-(4-O-methyl-alpha-rhamnopyranosyloxy)-3,4-dihydroquinolin-2(1H)-one

8-(4-O-methyl-alpha-rhamnopyranosyloxy)-3,4-dihydroquinolin-2(1H)-one

C16H21NO6 (323.1369)


   
   
   
   
   
   
   
   
   
   
   
   
   
   

SCHEMBL10716722

SCHEMBL10716722

C15H21N3O5 (323.1481)


   

Naftifine HCl

Naftifine HCl

C21H22ClN (323.1441)


   

C17H17N5O2_3-(1H-Imidazol-4-ylmethyl)-6-(1H-indol-3-ylmethyl)-2,5-piperazinedione

NCGC00385408-01_C17H17N5O2_3-(1H-Imidazol-4-ylmethyl)-6-(1H-indol-3-ylmethyl)-2,5-piperazinedione

C17H17N5O2 (323.1382)


   

gliclazide

gliclazide

C15H21N3O3S (323.1304)


A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BB - Sulfonylureas D007004 - Hypoglycemic Agents

   
   
   
   
   

2-[(4-phenylpiperazin-1-yl)methyl]-1-benzothiophen-5-amine

2-[(4-phenylpiperazin-1-yl)methyl]-1-benzothiophen-5-amine

C19H21N3S (323.1456)


   

Metiapine

Metiapine

C19H21N3S (323.1456)


C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent

   

2-(2-Piperidin-1-ylethoxy)benzaldehyde

2-(2-Piperidin-1-ylethoxy)benzaldehyde

C16H21NO6 (323.1369)


   

tert-butyl 4-(5-nitropyridin-2-yl)oxypiperidine-1-carboxylate

tert-butyl 4-(5-nitropyridin-2-yl)oxypiperidine-1-carboxylate

C15H21N3O5 (323.1481)


   

tert-butyl 4-(3-nitropyridin-2-yl)oxypiperidine-1-carboxylate

tert-butyl 4-(3-nitropyridin-2-yl)oxypiperidine-1-carboxylate

C15H21N3O5 (323.1481)


   

Boc-L-aspartic acid 4-benzyl ester

Boc-L-aspartic acid 4-benzyl ester

C16H21NO6 (323.1369)


   

Renzapride

Renzapride

C16H22ClN3O2 (323.14)


Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist[1]. Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study[2].

   

(2S)-2-phenyl-2-[[(1S)-1-[4-(trifluoromethyl)phenyl]propyl]amino]ethanol

(2S)-2-phenyl-2-[[(1S)-1-[4-(trifluoromethyl)phenyl]propyl]amino]ethanol

C18H20F3NO (323.1497)


   

N-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide

N-cyclopropyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide

C15H22BNO4S (323.1363)


   

H-Ala-Tyr-Ala-OH

(2S)-2-[[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]propanoic Acid

C15H21N3O5 (323.1481)


   
   

METHYL (2S,5R)-1-CBZ-5-HYDROXY-6-METHOXYPIPECOLINATE

METHYL (2S,5R)-1-CBZ-5-HYDROXY-6-METHOXYPIPECOLINATE

C16H21NO6 (323.1369)


   

N-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-4-pyrazolyl)butane-1-sulfonamide

N-(1,5-Dimethyl-3-oxo-2-phenyl-2,3-dihydro-4-pyrazolyl)butane-1-sulfonamide

C15H21N3O3S (323.1304)


   

(4-(4-Aminoquinazolin-2-yl)piperazin-1-yl)(furan-2-yl)methanone

(4-(4-Aminoquinazolin-2-yl)piperazin-1-yl)(furan-2-yl)methanone

C17H17N5O2 (323.1382)


   

3-[2-(1-PIPERIDINYL)ETHOXY]BENZALDEHYDE OXALATE

3-[2-(1-PIPERIDINYL)ETHOXY]BENZALDEHYDE OXALATE

C16H21NO6 (323.1369)


   

Boc-D-Asp-OBzl

Boc-D-Asp-OBzl

C16H21NO6 (323.1369)


   

Disperse Orange 25

Disperse Orange 25

C17H17N5O2 (323.1382)


   

Z-Asp(OtBu)-OH.H2O

Z-Asp(OtBu)-OH.H2O

C16H21NO6 (323.1369)


   
   

Mycophenolic acid D3

Mycophenolic acid D3

C17H17D3O6 (323.1448)


   

BOC-GLU-PHENYL ESTER

BOC-GLU-PHENYL ESTER

C16H21NO6 (323.1369)


   

Boc-D-Aspartic acid 4-benzyl ester

Boc-D-Aspartic acid 4-benzyl ester

C16H21NO6 (323.1369)


   

3-(4-(Trifluoromethyl)phenoxy)-N,N-dimethyl-3-phenylpropan-1-amine

3-(4-(Trifluoromethyl)phenoxy)-N,N-dimethyl-3-phenylpropan-1-amine

C18H20F3NO (323.1497)


   

4-(1,1-Dioxido-2-isothiazolidinyl)phenylboronic Acid Pinacol Ester

4-(1,1-Dioxido-2-isothiazolidinyl)phenylboronic Acid Pinacol Ester

C15H22BNO4S (323.1363)


   

11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine

11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine

C19H21N3S (323.1456)


   
   

2-chloro-N-cyclopentyl-5-(3,3-diethoxy-1-propyn-1-yl)-4-Pyrimidinamine

2-chloro-N-cyclopentyl-5-(3,3-diethoxy-1-propyn-1-yl)-4-Pyrimidinamine

C16H22ClN3O2 (323.14)


   

1-(4-FLUOROPHENYL)-4-ISOPROPYL-2-PHENYL-1H-PYRROLE-3-CARBOXYLICACID

1-(4-FLUOROPHENYL)-4-ISOPROPYL-2-PHENYL-1H-PYRROLE-3-CARBOXYLICACID

C20H18FNO2 (323.1321)


   

4-(4-methylphenyl)-2,2:6,2-terpyridine

4-(4-methylphenyl)-2,2:6,2-terpyridine

C22H17N3 (323.1422)


   

4-(2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholine

4-(2-Chloro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)morpholine

C16H23BClNO3 (323.1459)


   

N-[cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide

N-[cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl]propane-1-sulfonamide

C14H21N5O2S (323.1416)


D - Dermatologicals > D11 - Other dermatological preparations > D11A - Other dermatological preparations > D11AH - Agents for dermatitis, excluding corticosteroids C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor > C172200 - JAK Inhibitor D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

   

Remetinostat

Remetinostat

C16H21NO6 (323.1369)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C471 - Enzyme Inhibitor > C1946 - Histone Deacetylase Inhibitor C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent

   

Benzamide, 4-amino-N-1-azabicyclo(3.3.1)non-4-yl-5-chloro-2-methoxy-

Benzamide, 4-amino-N-1-azabicyclo(3.3.1)non-4-yl-5-chloro-2-methoxy-

C16H22ClN3O2 (323.14)


   

Tolmicen

Tolmicen

C20H21NOS (323.1344)


D000890 - Anti-Infective Agents > D000935 - Antifungal Agents C254 - Anti-Infective Agent > C514 - Antifungal Agent

   

Tolciclate

Tolciclate

C20H21NOS (323.1344)


D - Dermatologicals > D01 - Antifungals for dermatological use > D01A - Antifungals for topical use D000890 - Anti-Infective Agents > D000935 - Antifungal Agents

   

H-Ala-ala-tyr-OH

H-Ala-ala-tyr-OH

C15H21N3O5 (323.1481)


   

5-(4-Chlorophenyl)-2,2-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentane-1,3-diol

5-(4-Chlorophenyl)-2,2-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentane-1,3-diol

C16H22ClN3O2 (323.14)


   

1-[(2r)-2-Aminobutanoyl]-N-(3-Chlorobenzyl)-L-Prolinamide

1-[(2r)-2-Aminobutanoyl]-N-(3-Chlorobenzyl)-L-Prolinamide

C16H22ClN3O2 (323.14)


   

Renzaprida

Renzaprida

C16H22ClN3O2 (323.14)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists

   

2-[2-[(2-Amino-3-phenylpropanoyl)amino]propanoylamino]-3-hydroxypropanoic acid

2-[2-[(2-Amino-3-phenylpropanoyl)amino]propanoylamino]-3-hydroxypropanoic acid

C15H21N3O5 (323.1481)


   

1-[(1,2-Dimethyl-5-indolyl)methyl]-3-(phenylmethyl)thiourea

1-[(1,2-Dimethyl-5-indolyl)methyl]-3-(phenylmethyl)thiourea

C19H21N3S (323.1456)


   
   
   
   
   
   
   
   
   
   
   
   
   

6-Aminopenicilloyl-benzylamine

6-Aminopenicilloyl-benzylamine

C15H21N3O3S (323.1304)


   

2-Phenylamino-4,6-diphenylpyrimidine

2-Phenylamino-4,6-diphenylpyrimidine

C22H17N3 (323.1422)


   

Octanal O-[(pentafluorophenyl)methyl]oxime

Octanal O-[(pentafluorophenyl)methyl]oxime

C15H18F5NO (323.1308)


   

5-(Diethoxymethyl)-3-[(diethoxyphosphinyl)methyl]-2-isoxazoline

5-(Diethoxymethyl)-3-[(diethoxyphosphinyl)methyl]-2-isoxazoline

C13H26NO6P (323.1498)


   
   
   
   

(S)-Renzapride

(S)-Renzapride

C16H22ClN3O2 (323.14)


(S)-Renzapride ((S)-BRL 24924) is the isomer of HY-14147 Renzapride. Renzapride is a 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride also is a 5HT2b and 5HT3 receptor antagonist. Renzapride can be used for constipation predominant irritable bowel syndrome (C-IBS) study[1][2].

   

(3r)-3-(4-methoxy-5-methyl-6-oxopyran-2-yl)butyl (2r)-5-hydroxy-3,4-dihydro-2h-pyrrole-2-carboxylate

(3r)-3-(4-methoxy-5-methyl-6-oxopyran-2-yl)butyl (2r)-5-hydroxy-3,4-dihydro-2h-pyrrole-2-carboxylate

C16H21NO6 (323.1369)


   

2-{[(4-butanoyl-3-methoxy-5-methylphenyl)(hydroxy)methylidene]amino}-3-hydroxypropanoic acid

2-{[(4-butanoyl-3-methoxy-5-methylphenyl)(hydroxy)methylidene]amino}-3-hydroxypropanoic acid

C16H21NO6 (323.1369)


   

2-(hydroxymethyl)-6-[3-(methoxymethyl)indol-1-yl]oxane-3,4,5-triol

2-(hydroxymethyl)-6-[3-(methoxymethyl)indol-1-yl]oxane-3,4,5-triol

C16H21NO6 (323.1369)


   

5-methyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl acetate

5-methyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl acetate

C16H21NO6 (323.1369)


   

n-[1-(4,5-dihydroxy-6-methyloxan-2-yl)-2-hydroxypyrimidin-4-ylidene]-3-methylbut-2-enamide

n-[1-(4,5-dihydroxy-6-methyloxan-2-yl)-2-hydroxypyrimidin-4-ylidene]-3-methylbut-2-enamide

C15H21N3O5 (323.1481)


   

(2s,3r,4s,5s,6r)-2-[(3-ethyl-1h-indol-4-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-[(3-ethyl-1h-indol-4-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C16H21NO6 (323.1369)


   

(1r,5s,16s)-5-methyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl acetate

(1r,5s,16s)-5-methyl-3,7-dioxo-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadec-10-en-5-yl acetate

C16H21NO6 (323.1369)


   

(2s)-1-[(3-acetyl-2-hydroxy-4,6-dimethoxyphenyl)methyl]pyrrolidine-2-carboxylic acid

(2s)-1-[(3-acetyl-2-hydroxy-4,6-dimethoxyphenyl)methyl]pyrrolidine-2-carboxylic acid

C16H21NO6 (323.1369)


   

(2s)-2-{[(4-butanoyl-3-methoxy-5-methylphenyl)(hydroxy)methylidene]amino}-3-hydroxypropanoic acid

(2s)-2-{[(4-butanoyl-3-methoxy-5-methylphenyl)(hydroxy)methylidene]amino}-3-hydroxypropanoic acid

C16H21NO6 (323.1369)


   

(2r,3r,4r)-2,3,4,5-tetrahydroxypentyl (2s)-2-(1h-indol-3-yl)propanoate

(2r,3r,4r)-2,3,4,5-tetrahydroxypentyl (2s)-2-(1h-indol-3-yl)propanoate

C16H21NO6 (323.1369)


   

methyl (4ar,7ar)-7-(hydroxymethyl)-2-(4-methoxy-4-oxobutyl)-1-oxo-4ah,5h,7ah-cyclopenta[c]pyridine-4-carboxylate

methyl (4ar,7ar)-7-(hydroxymethyl)-2-(4-methoxy-4-oxobutyl)-1-oxo-4ah,5h,7ah-cyclopenta[c]pyridine-4-carboxylate

C16H21NO6 (323.1369)


   

methyl 7-(hydroxymethyl)-2-(4-methoxy-4-oxobutyl)-1-oxo-4ah,5h,7ah-cyclopenta[c]pyridine-4-carboxylate

methyl 7-(hydroxymethyl)-2-(4-methoxy-4-oxobutyl)-1-oxo-4ah,5h,7ah-cyclopenta[c]pyridine-4-carboxylate

C16H21NO6 (323.1369)


   

n-{1-[(2r,4r,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]-2-hydroxypyrimidin-4-ylidene}-3-methylbut-2-enamide

n-{1-[(2r,4r,5s,6r)-4,5-dihydroxy-6-methyloxan-2-yl]-2-hydroxypyrimidin-4-ylidene}-3-methylbut-2-enamide

C15H21N3O5 (323.1481)


   

2-[(2-hydroxy-3,4-dihydroquinolin-8-yl)oxy]-5-methoxy-6-methyloxane-3,4-diol

2-[(2-hydroxy-3,4-dihydroquinolin-8-yl)oxy]-5-methoxy-6-methyloxane-3,4-diol

C16H21NO6 (323.1369)


   

2,3,4,5-tetrahydroxypentyl 2-(1h-indol-3-yl)propanoate

2,3,4,5-tetrahydroxypentyl 2-(1h-indol-3-yl)propanoate

C16H21NO6 (323.1369)